Trial Profile
Safety and efficacy of carfilzomib in patients with relapsed/refractory myeloma through compassionate use named patient program: Norwegian retrospective study
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 25 Jul 2018
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary)
- Indications Myeloma
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 25 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association